Phase 2 study to assess safety and efficacy of OBE022 to delay birth after oral administration in pregnant women

Trial Profile

Phase 2 study to assess safety and efficacy of OBE022 to delay birth after oral administration in pregnant women

Planning
Phase of Trial: Phase II

Latest Information Update: 18 May 2017

At a glance

  • Drugs OBE 022 (Primary)
  • Indications Preterm labour
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 May 2017 ObsEva expects to initiate this trial in 2H 2017, according to a company media release.
    • 17 Jan 2017 New trial record
    • 13 Jan 2017 According to an ObsEva media release, company plans to initiate this study in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top